Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma.

ABSTRACT:

Background

Pleural mesothelioma (PM) is a rare cancer with a dismal prognosis. Dual immune checkpoint inhibitors have improved overall survival, but the rate of immune-related adverse events (irAEs) is high. Serum cytokines reflect systemic immune reactions and may serve as biomarkers for irAEs.

Patients and methods

Patients with pleural mesothelioma treated with nivolumab and ipilimumab with or without UV1 vaccine in the NIPU study were included. Serum cytokine levels were measured by Bio-Plex Pro Human Cytokine Screening 48-Plex Panel Assay. Correlations between cytokine levels and irAEs were analyzed by generalized linear mixed models to identify potential diagnostic and predictive biomarkers.

Results

Higher levels of MIG, eotaxin, MIP-1α, IP-10, TNF-α, MIP-1β, IL-

SUBMITTER: Farooqi SJ 

PROVIDER: S-EPMC11647018 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature